Glycoxidation andwound healing in diabetes: An interesting relationship

Current Diabetes Reviews

Volumn 7, Issue 6, 2011, Pages 416-425

  Peppa, Melpomeni ^a   Raptis, Sotirios A ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic National Diabetes Center   (Greece)

Author keywords

Ncarboxymethyllysine (CML); Advanced glycation end products; AGE; Diabetic wound healing; Inflammation; Methylglyoxal (MG); Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; BENFOTIAMINE; C REACTIVE PROTEIN; COLLAGEN; ELASTIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; INTERSTITIAL COLLAGENASE; LAMININ; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TUBULIN; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; AORTA ATHEROSCLEROSIS; APOPTOSIS; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARBOHYDRATE METABOLISM; CELL ADHESION; CELL CYCLE ARREST; CELL PROLIFERATION; COLLAGEN SYNTHESIS; DEMENTIA; DETOXIFICATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; ENZYME GLYCOSYLATION; EPITHELIZATION; GENE EXPRESSION; GLYCOSYLATION; GRANULATION TISSUE; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; MICROALBUMINURIA; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; SCIATIC NEUROPATHY; SKIN INFLAMMATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; WOUND CLOSURE; WOUND CONTRACTION; WOUND HEALING; WOUND HEALING IMPAIRMENT; DIABETIC ANGIOPATHY; INJURY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 80054062181     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339911797579188     Document Type: Article

References (139)

1. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361(9368): 1545-1551.
2. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159(2): 513-525.
3. Peppa M, Brem H, Ehrlich P, et al. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003; 52(11): 2805-2813.
4. Peppa M, Stavroulakis P, Raptis SA. Advanced glycoxidation products and impaired diabetic wound healing. Wound Repair Regen 2009; 17(4): 461-472.
5. Peppa M, Uribarri J, Vlassara H. Glucose and the advanced glycosylation end products. In: Diabetes and Cardiovascular Disease (second edition). A. Veves, ed., Humana Press, Totowa, New Jersey, 2005; 81-102.
6. Peppa M, Vlassara H. Advanced glycation end products and diabetic complications: a general overview. Hormones 2005; 4(1): 28-33.
7. Peppa M, SA Raptis. Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev 2008; 4: 1-9.
8. Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 2004; 4(1): 31-36.
9. Peppa M, Uribarri J, Vlassara H. Advanced glycoxidation: A new risk factor for cardiovascular disease? Cardiovascular Toxicology 2002; 2 (4): 275-287.
10. Uribarri J, Peppa M, Vlassara H. Diabetes and advanced glycation end products: New mechanisms and clinical relevance. A.Veves, ed., Humana Press, Totowa, New Jersey, 2010 (in press)
11. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates N (epsilon)-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999; 104: 103-113.
12. Vander Jagt DL, Hassebrook RK, Hunsaker LA, Brown WM, Royer RE. Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications. Chem Biol Interact 2001; 130-132(1-3): 549-562.
13. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104(8): 1287-1291.
14. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110(6): 911-916.
15. Silván JM, van de Lagemaat J, Olano A, Del Castillo MD. Analysis and biological properties of amino acid derivates formed by Maillard reaction in foods. J Pharm Biomed Anal 2006; 41(5): 1543-1551
16. Forster A, Kühne Y, Henle T. Studies on absorption and elimination of dietary maillard reaction products. Ann N Y Acad Sci 2005; 1043: 474-481.
17. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8(7): 337-346.
18. Lin RY, Choudhury RP, Cai W, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003; 168(2): 213-220.
19. Lin RY, Reis ED, Dore AT, et al. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002; 163(2): 303-311.
20. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002; 18(3): 224-237.
21. Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003; 52(6): 1441-1448.
22. Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2002; 51(7): 2082-2089.
23. Hofmann SM, Dong HJ, Li Z, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2005; 54(8): 2314-2319
24. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99(24): 15596-15601.
25. Cai W, He JC, Zhu L, et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004; 110(3): 285-291.
26. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14(3): 728-731.
27. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004; 43(4): 690-695.
28. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005; 1043: 461-466.
29. Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62(4): 427-433.
30. Palinski W, Koschinsky T, Butler SW, et al. Immunological evidence for the presence of advanced glycation end products in atherosclerotic lesions of euglycemic rabbits. Arter Thromb Vasc Biol 1995; 15: 571-582.
31. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997, 99: 457-468.
32. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003; 21(1): 3-12.
33. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004; 64(5): 459-470.
34. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 2001; 10(11): 1977-1987.
35. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004; 17(12 Pt 2): 23S-30S.
36. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270(18): 10828-10832.
37. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci 1993; 90: 6434-6438.
38. Galle J, Schneider R, Winner B, et al. Glycoxidized LDL impair endothelial function more potently than oxidized LDL: role of enhanced oxidative stress. Atherosclerosis 1998; 138: 65-77.
39. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997; 27(2): 97-108.
40. Tan KC, Chow WS, Ai VH, et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002; 25(6): 1055-1059.
41. Jin C, Lu L, Zhang RY, et al. Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta 2009; 408(1-2): 45-49.
42. Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005; 54(3): 345-350.
43. Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a populationbased 18 year follow-up study. Diabetologia 2007; 50(7): 1409-1417.
44. Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006; 103(37): 13801-13806.
45. Cai W, He JC, Zhu L, Chen X, Striker GE, Vlassara H. AGEreceptor- 1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 2008; 294(1): C145-C525.
46. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108(7): 949-955.
47. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006, 29(9): 2064-2071.
48. Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007; 30(10): 2579-2582.
49. Bendayan M. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 1998; 54(2): 438-447.
50. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic glomerular lesions. Implications for oxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004.
51. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of noncarboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diab Complic 2003; 17(1): 16-21.
52. Genuth S, Sun W, Cleary P, et al. DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005; 54: 3103-3111.
53. Bolton WK, Cattran DC, Williams ME, et al. ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.
54. Peppa M, Brem H, Cai W, et al. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 2006; 6: 430-436.
55. Sulochana KN, Ramprasad S, Coral K, et al. Glycation and glycoxidation studies in vitro on isolated human vitreous collagen. Med Sci Monit 2003; 9(6): BR219-BR223.
56. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997; 150(2): 523-531.
57. Matsumoto Y, Takahashi M, Chikuda M, Arai K. Levels of mature cross-links and advanced glycation end product cross-links in human vitreous. Jpn J Ophthalmol 2002; 46(5): 510-517.
58. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9(3): 294-299.
59. Fosmark DS, Bragadóttir R, Stene-Johansen I, et al. Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study. Acta Ophthalmol Scand 2007; 85: 618-622.
60. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of noncarboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diab Complic 2003; 17(1): 16-21.
61. Boehm BO, Schilling S, Rosinger S, et al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004; 47: 1376-1379.
62. Koga K, Yamagishi S, Okamoto T, et al. Serum levels of glucosederived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res 2002; 22(1): 13-17.
63. Cullum NA, Mahon J, Stringer K, McLean WG. Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus. Diabetologia 1991; 34(6): 387-389.
64. Graham AR, Johnson PC. Direct immunofluorescence findings in peripheral nerve from patients with diabetic neuropathy. Ann Neurol 1985; 17(5): 450-454.
65. Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S. Localization in human diabetic peripheral nerve of N (epsilon)- carboxymethyllysine-protein adducts, and advanced glycation endproduct. Diabetologia 1997; 40(12): 1380-1387.
66. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci USA 1981; 78(8): 5190-5192.
67. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol 1996; 55(12): 1181-1193.
68. Poduslo JF, Curran GL. Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Brain Res Mol Brain Res 1994; 23(1-2): 157-162.
69. Southern L, Williams J, Esiri MM. Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia. BMC Neurol 2007; 16: 35.
70. Ahmed N, Ahmed U, Thornalley PJ, et al. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2005; 92: 255-263.
71. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341(10): 738-746.
72. Calvin M. Cutaneous wound repair. Wounds 1998; 10(1): 12-32.
73. Gailit J, Clark RA. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol 1994; 6(5): 717-725.
74. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001; 69(4): 513-521.
75. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994; 8(8): 504-512.
76. Peter A, Ward MD, Alex B, Lentsch P. The acute inflammatory response and its regulation. Arch Surg 1999; 134: 666-669.
77. Leibovich SJ, Ross R. The role of macrophage in wound repair: a study with hydrocortisone and antimacrophage serum. Am J Pathol 1975; 78(1): 71-100.
78. Campbell EJ, Cury JD, Shapiro SD, Goldberg GI, Welgus HG. Neutral proteases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J Immunol 1991; 146(4): 1286-1293.
79. Chen J, Kasper M, Heck T, et al. Tissue factor as a link between wounding and tissue repair. Diabetes 2005; 54(7): 2143-2154.
80. Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000; 49(9): 1451-1458.
81. Bagdade JD, Stewart M, Walters E. Impaired granulocyte adherence. A reversible defect in host defense with poorly controlled diabetes. Diabetes 1978; 27(6): 677-681.
82. Chang FY, Shaio MF. Respiratory burst activity of monocytes from patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995; 29(2): 121-127.
83. Armstrong DG, Nguyen HC. Improvement in healing with aggressive edema reduction after debridement of foot infection in persons with diabetes. Arch Surg 2000; 135(12): 1405-1409.
84. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in nonhealing and healing chronic leg ulcers. Wound Repair Regen 2000; 8(1): 13-25.
85. Wetzler C, Kämpfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol 2000; 115(2): 245-253.
86. Kämpfer H, Schmidt R, Geisslinger G, Pfeilschifter J, Frank S. Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to COX1 activity in diabetes-impaired wound healing Diabetes 2005; 54(5): 1543-1551.
87. Soneja A, Drews M, Malinski T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep 2005; 57 Suppl: 108-119.
88. Li Y, Ferrante A, Poulos A, Harvey DP. Neutrophil oxygen radical generation: synergistic responses to tumor necrosis factor and mono-polyunsaturated fatty acids. J Clin Invest 1996; 97(7): 1605-16059.
89. Musalmah M, Fairuz AH, Gapor MT, Ngah WZ. Effect of vitamin E on plasma malondialdehyde, antioxidant enzyme levels and the rates of wound closures during wound healing in normal and diabetic rats. Asia Pac J Clin Nutr 2002; 11 Suppl 7: S448-S451.
90. O'Toole EA, Marinkovich MP, Peavey CL, et al. Hypoxia increases human keratinocyte motility on connective tissue. J Clin Invest 1997; 100(11): 2881-2891.
91. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83(3): 835-870.
92. Schultz G, Rotatori DS, Clark W. EGF and TGF-alpha in wound healing and repair. J Cell Biochem 1991; 45(4): 346-352.
93. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Circ Res 1995; 77(3): 638-643.
94. Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995; 270(21): 12607-12613.
95. Pilcher BK, Wang M, Qin XJ, Parks WC, Senior RM, Welgus HG. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann N Y Acad Sci 1999; 878: 12-24.
96. Katz MH, Alvarez AF, Kirsner RS, Eaglstein WH, Falanga V. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol 1991; 25(6 Pt 1): 1054-1058.
97. Lynch SE, Nixon JC, Colvin RB, Antoniades HN. Role of plateletderived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci USA 1987; 84(21): 7696-7700.
98. Yamada KM. Fibronectin peptides in cell migration and wound repair. J Clin Invest 2000; 105(11): 1507-1509.
99. Greiling D, Clark RA. Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. J Cell Sci 1997; 110(Pt 7): 861-870.
100. Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261(9): 4337-4345.
101. Doxey DL, Ng MC, Dill RE, Iacopino AM. Platelet-derived growth factor levels in wounds of diabetic rats. Life Sci 1995; 57(11): 1111-1123.
102. Altavilla D, Saitta A, Cucinotta D, et al. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 2001; 50(3): 667-674.
103. Trengove NJ, Stacey MC, MacAuley S, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7(6): 442-452.
104. Lobmann R, Pap T, Ambrosch A, Waldmann K, König W, Lehnert H. Differential effects of PDGF-BB on matrix metalloproteinases and cytokine release in fibroblasts of type 2 diabetic patients and normal controls in vitro. J Diab Complic 2006; 20(2): 105-112.
105. Loot MA, Kenter SB, Au FL, et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-1, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002; 81(3): 153-160.
106. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction of the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003; 162(1): 303-312.
107. Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T, Wertheimer E. Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes 2001; 50(7): 1627-1635.
108. Al-Mashat HA, Kandru S, Liu R, Behl Y, Desta T, Graves DT. Diabetes enhances mRNA levels of propapoptotic genes and caspase activity, which contribute to impaired wound healing. Diabetes 2006; 55(2): 487-495.
109. Liu R, Desta T, He H, Graves DT. Diabetes alters the response to bacteria by enhancing fibroblast apoptosis. Endocrinology 2004; 145(6): 2997-3003.
110. Tsuboi R, Rifkin DB. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impaired db/db mice. J Exp Med 1990; 172(1): 245-251.
111. Grinnell F. Fibroblasts, myofibroblasts and wound contraction. J Cell Biol 1994; 124(4): 401-404.
112. Montesano R, Orci L. Transforming growth factor β stimulates collagen matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci USA 1988; 85(13): 4894-7.
113. Kessler D, Dethlefsen S, Haase I, et al. Fibroblasts in mechanically stressed collagen lattices assume a synthetic phenotype. J Biol Chem 2001; 276(39): 36575-36585.
114. Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor β1. Am J Respir Cell Mol Biol 1999; 21(6): 658-6565.
115. Desmoulière A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during transition between granulation tissue and scar. Am J Pathol 1995; 146(1): 56-66.
116. Collison KS, Parhar RS, Saleh SS, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002; 71(3): 433-444.
117. Liu BF, Miyata S, Kojima H, et al. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes 1999; 48(10): 2074-2082.
118. Teixeira AS, Caliari MV, Rocha OA, Machado RD, Andrade SP. Aminoguanidine prevents impaired healing and deficient angiogenesis in diabetic rats. Inflammation 1999; 23(6): 569-581.
119. Berlanga J, Cibrian D, Guillén I, et al. Methylglyoxal administration induces diabetes-like microvascular changes and pertubs the healing process of cutaneous wounds. Clin Sci (Lond) 2005; 109(1): 83-95.
120. Wong RK, Pettit AI, Quinn PA, Jennings SC, Davies JE, Ng LL. Advanced glycation end products stimulate an enhanced neutrophil respiratory burst mediated through the activation of cytosolic phospholipase A2 and generation of arachidonic acid. Circulation 2003; 108(15): 1858-1864.
121. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269(13): 9889-9897.
122. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280(5): E685-E694.
123. Li Y, Ferrante A, Poulos A, Harvey DP. Neutrophil oxygen radical generation: synergistic responses to tumor necrosis factor and mono-polyunsaturated fatty acids. J Clin Invest 1996; 97(7): 1605-1609.
124. Rojas A, Caveda L, Romay C, et al. Effect of advanced glycosylation end products on the induction of nitric oxide synthase in murine macrophages. Biochem Biophys Res Commun 1996; 225(2): 358-362.
125. Schmidt AM, Weidman E, Lalla E, et al. Advanced glycation end products (AGEs) induce oxidant stress in the gingiva: a potential mechanism underlying accelerated periodontal disease associated with diabetes. J Periodontal Res 1996; 31(7): 508-515.
126. Teixeira AS, Andrade SP. Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Life Sci 1999; 64(8): 655-662.
127. Morita K, Urabe K, Moroi Y, et al. Migration of keratinocytes is impaired on glycated collagen I. Wound Repair Regen 2005; 13(1): 93-101.
128. Paul RG, Bailey AJ. The effect of advanced glycation end product formation upon cell matrix interactions. Int J Biochem Cell Biol 1993; 31(6): 653-660.
129. Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 1998; 106(1-2): 1-56.
130. Kazuhiro Y, Tomohide O, Tomonobu Y, Masatoshi B. Inhibitory effect of peptide free forms of advanced glycation end products on the proliferation and extracellular matrix production of cultured cells. J Heal Sci 2001; 47(3): 296-301.
131. Alikhani Z, Alikhani M, Boyd CM, Nagao K, Trackman PC, Graves DT. Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem 2005; 280(13): 12087-12095.
132. Alikhani M, Maclellan CM, Raptis M, Vora S, Trackman PC, Graves DT. Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am J Physiol Cell Physiol 2007; 292(2): C850-C856.
133. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94(1): 110-117.
134. Duraisamy Y, Slevin M, Smith N, et al. Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis 2001; 4(4): 277-288.
135. Portero-Otín M, Pamplona R, Bellmunt MJ, et al. Advanced glycation end product precursors impair epidermal growth factor receptor signalling. Diabetes 2002; 51(5): 1535-1542.
136. Niu Y, Xie T, Ge K, Lin Y, Lu S. Effects of extracellular matrix glycosylation on proliferation and apoptosis of human dermal fibroblasts via the receptor for advanced glycosylated end products. Am J Dermatopathol 2008; 30(4): 344-351.
137. Yavuz D, Tuǧtepe H, Cetinel S, et al. Collagen ultrastructure and TGF-beta1 expression preserved with aminoguanidine during wound healing in diabetic rats. Endocr Res 2005; 31(3): 229-243.
138. Howard EW, Benton R, Ahern-Moore J, Tomasek JJ. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp Cell Res 1996; 228(1): 132-137.
139. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3(5): 349-363.